Purpose of review PremRNA alternative splicing is more a rule than an exception as it affects more than 90% of multiexons genes and plays a key role in proteome diversity. Here, we discuss some recent studies published in the extensively growing field linking RNA splicing and cancer.
INTRODUCTION
In eukaryotes, gene expression is finely controlled by complex regulatory processes that affect all steps of RNA expression, extending from transcription to maturation in the nucleus, mRNA cytosolic export, stability, and translation. One of the crucial steps inside this network is the premRNA constitutive splicing process during which intronic sequences are removed from the premRNA and exonic sequences joined to form the mature mRNA. Another level of regulation during this process is represented by alternative splicing. Through the use of alternative promoters, alternative polyadenylation sites, retained introns or alternatively spliced exons (exon cassette or mutually exclusive exon), alternative splicing leads to the generation of several coding and noncoding mRNA variants from the same gene. Therefore, one of the main consequences of alternative splicing is to remodel the proteome through the synthesis of various protein isoforms displaying different biological activities. This process is tightly controlled across different tissues and developmental stages, and dysregulation of alternative splicing is closely associated with various human diseases, including cancer. The identification of the alternative splicing isoforms expressed in tumors is therefore of utmost relevance to unravel novel oncogenic mechanisms and for the development
DYSREGULATION OF ALTERNATIVE SPLICING: ONE OF THE HALLMARKS OF CANCER
In the last decade, the development of highthroughput studies as well as the improvement of bioinformatic tools have extensively increased the amount of expression data regarding splice variants in cancer, and unraveled the existence of cancerspecific splicing patterns that likely contribute to tumor progression through modulation of every aspect of cancer cell biology [1, 2] . Accordingly, by analyzing RNA-Seq databases from the Cancer Genome Atlas project, three studies published this year characterized novel splicing signatures in different cancer types [3 & ,4
& ,5]. Many of these cancer-associated splicing events were functionally associated with cell cycle control, cytoskeletal organization, migration, cell-cell adhesion, and more unexpectedly insulin signaling pathway. Importantly, these splicing events allowed to separate cancer from normal tissues, to distinguish distinct cancer types (i.e., breast carcinoma vs. lung cancer) or histological subtypes within the same cancer type [i.e., lung adenocarcinoma (LUC) vs. squamous lung carcinoma], as well as to predict patient survival. As an example, Sebestyen and colleagues [4 & ] analyzed more than 4000 samples in nine different cancer types and found specific splicing signatures for basal-like breast tumors involving the tumor driver CTNND1. They also identified 244 isoform switches for which the relative expression change occurs in the most abundant isoform, suggesting that they may have a functional impact. Importantly, most of these switches were independent of somatic mutations, indicating that alterations in chromatin structure or aberrant expression of splicing factors could explain these splicing events. Consistently, deregulation of specific splicing regulators, including RBFOX2, MBNL1/2, and QKI proteins was further found to account for hundreds of cassette exons for which splicing was altered in multiple cancer types [3 & ], highlighting these specific factors as critical regulators of cancerspecific alternative splicing. Overall, and although many splice variants might not be detected owing to their low abundance, these large scale studies unraveled a huge amount of cancer-altered splice events in distinct cancer types. Deepened investigations are now required to identify the functional consequences of these splicing events as well as the regulatory upstream signals that control them. Such studies are mandatory if we want to select those alternative splicing events that really contribute to the carcinogenesis process and are therefore prime targets for therapeutic purpose. As an example, exon array studies performed in nonsmall cell lung cancers have identified most prevalent tumor-associated changes in transcripts from genes which regulate angiogenesis, actin-cytoskeleton remodeling and WNT/NOTCH signaling, namely vascular endothelial growth factor-A (VEGF-A), microtubuleactin cross-linking factor 1, amyloid beta precursor protein, and the Numb (Drosophila) homolog [6] . QKI is frequently downregulated in lung cancer and its downregulation is significantly associated with a poorer prognosis. Consistently, QKI was later found to inhibit lung cancer cell growth at least in part through the regulation of the alternative splicing of Numb (Drosophila) homolog [7 & ]. These data are thus consistent with the fact that only a restricted number of splicing factors and alternative splicing events could be critical for cancer progression but distinct according to the tumor type. In addition, splicing regulators may play other functions than regulating 'classical' alternative splicing. The circRNAs result from a noncanonical form of alternative splicing most commonly where the splice donor site of one exon is ligated to the splice acceptor site of an upstream exon. As an example, the role of QKI in the 
FUNCTIONAL CONSEQUENCES OF MUTATIONS AFFECTING RNA SPLICING REGULATORS
The splicing process is carried out by the spliceosome, a complex macromolecular machinery constituted of five small nuclear ribonucleoprotein particles (U1, U2, U4, U5, and U6 snRNPs) and more than 200 ancillary proteins. Up to now, a growing number of studies have demonstrated abnormal expression (either downregulation or overexpression) of some spliceosome components in cancers. More recently, somatic mutations of splicing factors were identified in myelodysplastic syndrome (MDS) [9] , acute myeloid leukemia [(AML); The Cancer Genome Atlas (TCGA)] and LUC [10] . Importantly, they were mutually exclusive, suggesting that spliceosome mutations may have the same functional effect on oncogenesis. Until these last 18 months, it was poorly known how these mutations contribute to cancers. Hot spot mutations in SF3B1 at a residue lysine in position 700 occur in 16 and 6% of papillary and mucinous breast carcinoma [11] . Interestingly, SF3B1 mutation was associated with differentially spliced events in TMEM14C, RPL31, DYNL11, or ABCC5 genes, and more importantly SF3B1 mutant cell lines were found to be more sensitive to spliceostatin A, a SF3B complex inhibitor [11] . U2AF1, a 3 0 splice site recognition factor, has hot spot mutation at amino acid position 34 in AML, MDS, and LUC. Using TCGA databases, Brooks and colleagues [12] identified 131 and 369 splicing alterations significantly associated with U2AF1 mutation in LUC and AML respectively, with 30 splicing alterations being present in both cancer types, including three genes of the Cancer Gene Cesus, CTNNB1, CHCHD7, and phosphatidylinositol binding clathrin assembly protein. They also demonstrated that mutation of U2AF1 alters its binding to the 3 0 splice site sequence and causes preference for cytidine adenosine guanine over uridine adenosine guanine. More recently, Shirai and colleagues [13 && ] demonstrated that transgenic mice expressing mutant U2AF1 (S34F) in bone marrow cells display altered hematopoiesis and changes in premRNA splicing in hematopoietic progenitor cells affecting mainly RNA processing genes, ribosomal genes, and recurrently mutated MDS and AML-associated genes. Interestingly, both monocytes and B cells were reduced in U2AF1 (S34F) mutated mice and evidenced increased phospho-H2AX staining, suggesting that U2AF1 (S34F) mutation may have consequences for genome stability, which is reminiscent with missplicing being involved in the cotranscriptional formation of R-loops (RNA:DNA hybrid) leading to DNA double strand breaks. The SRSF2 protein is a member of the serine/arginine-rich protein family that contributes to both constitutive and alternative splicing. SRSF2 mutations on its P95 proline residue occur in 20-30% of MDS patients and are associated with adverse outcome [9] . Consistent with the critical role of SRSF2 mutation in MDS, hematopoietic-specific conditional SRSF2 knock-in mice, heterozygous for SRSF2-P95H mutation, developed myelodysplasia while SRSF2-deficient mice did not [14 && ]. This phenotype was associated with global alterations of gene expression affecting several hematopoietic regulators, including Gata1, Gata2, Cdkn1a, and Hoxb2. In addition, proline 95 mutations were found to change the RNA-binding specificity of SRSF2, thereby promoting the inclusion of a highly conserved 'poison' cassette exon of enhancer of zeste homolog 2, a histone methyltransferase belonging to the polycomb repressive complex 2, leading to nonsensemediated decay. This SRSF2 (P95H)-induced missplicing event could be relevant for MDS pathogenesis as restoring enhancer of zeste homolog 2 expression partially rescues hematopoiesis in SRSF2 mutant cells [14 && ]. Moreover, dysregulated splicing of U12-type intron in MDS was also associated with mutations of ZRSR2, an essential component of the minor spliceosome assembly [15] . Later on, germline and somatic mutations in the gene encoding for the DEAD-Box RNA helicase DDX41 were identified in myeloid neoplasms and were again mutually exclusive with mutations of other spliceosomal proteins [16 && ]. These mutations were shown to alter DDX41 interaction with major components of U2 (SF3B1) and U5 (PRPF8) spliceosomes and to lead to the missplicing of genes such as ZMYM2, a zinc finger protein involved in a histone deacetylase complex. Overall, these studies clearly evidence the role of splicing regulator mutation in triggering missplicing patterns in cancers (Fig. 1) . In addition, they highlight some epigenetic regulators as potential target genes of these mutated proteins. Although these mutations appear to be mutually exclusive, both mutation and deregulated expression (downregulation or overexpression) of distinct splicing factors cooccur in the same tumors. Further functional studies and mouse models are now needed to decipher whether and how these anomalies cooperate during the tumorigenic process.
NEW INSIGHTS LINKING RNA SPLICING AND INTRACELLULAR SIGNALING NETWORKS
Multiple posttranslational modifications have been shown to control the expression and/or the activity of splicing factors. However, how the RNA splicing machinery is connected within intracellular signaling networks and integrated within physiological stimuli is only an emerging field. Several recent studies provided new data in this setting. As a few examples, a previously unknown link was identified between iron homeostasis and a SRSF7-dependent control of the alternative splicing of the apoptosis Abnormal RNA splicing patterns deregulated mRNA levels defective proteins FIGURE 1. In tumors, alterations of core components of the spliceosome machinery that participate in all the steps of RNA splicing by binding to branch site, 3 0 splice or 5 0 splice site, or specific exonic sequences are illustrated. These alterations include mutations or deregulated expression. Concomitantly, various stressful stimuli can alter the expression and/or the activity of these proteins. This leads to aberrant splicing patterns in numerous target mRNAs, including intron retention or exon poison inclusion, which may reduce mRNA levels or generate truncated protein isoforms with defective functions. In this way, spliceosome alterations contribute to the hallmarks of cancer model proposed by Hanahan and Weinberg, leading to tumor progression as well as to tumor escape from therapy. Alterations of the spliceosome machinery and more generally global RNA splicing defects may render tumor cells sensitive to spliceosome inhibition, therefore providing an Achilles heel for future therapeutic strategies. ESE, exonic splicing element; ISE, intronic splicing element.
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repair. All these mechanisms are collectively termed the DNA damage response (DDR). These last years, numerous cross-talks between DDR and RNA splicing have emerged which unraveled splicing factors as critical contributors of DDR through prevention of R-loops formation or interaction with components of the DNA repair machinery [20] . Modulating the expression and/or activity of RNA splicing factors could therefore offer alternative therapeutic strategies to increase the sensitivity of cancer cells in combination with classical chemotherapies. Three recent studies further deepened this connection. In quiescent cells, Tresini and colleagues [21 && ] demonstrated that transcriptionblocking DNA lesions caused by UV irradiations deplete chromatin in late-maturation stage spliceosomes, namely U2 and U5 snRNPs, by inducing their relocalization. Such displacement leads to Rloops formation and activation of a noncanonical ataxia telangiectasia mutated (ATM) signaling pathway that prevents further spliceosome organization through a forward feedback loop and alters alternative splicing [21 && ]. In addition, in a transgenic mouse model that mimicks progressive telomere erosion and persistent DNA damage signaling, altered differentiation of common myeloid progenitors and occurrence of a MDS phenotype were associated with the repression of mRNA splicing/ processing genes including SRSF2, as well as with aberrant splicing of genes involved in genome stability, DNA repair or chromatin remodeling such as the DNA methyltransferase DNMT3A [22 && ]. Interestingly, a correlation between activation of the ATR kinase and decreased SRSF2 levels was found in MDS CD34 þ patients' cells, suggesting that ATR may regulate SRSF2 expression. Overall, these studies reinforce the previously published connection between ATM, ATR, and some components of the spliceosome [23] . Another study showed that a major gatekeeper of genome stability, namely breast cancer 1 (BRCA1), interacts with and recruits the mRNA-splicing machinery onto BRCA1/ BCLAF1 target genes in response to DNA damage, thereby promoting transcript stability and protein expression. Importantly, the depletion of BRCA1, BCLAF1, or other spliceosome members of this complex resulted in sensitivity to DNA damage and defective DNA repair [24 && ]. This study provides evidence that key DDR components also contribute to premRNA alternative splicing of specific target genes. Therefore, RNA splicing machinery controls DNA damage machinery and 'vice versa'. As DDR is a critical gatekeeper against genome instability, such interplay provides an additional mechanism by which aberrant RNA splicing could contribute to tumorigenesis.
THERAPEUTIC STRATEGIES TARGETING RNA SPLICING IN CANCER: PROOFS OF PRINCIPLE
Aberrant premRNA splicing promotes cell survival in response to chemotherapy through the deregulation of genes involved in apoptosis or alteration in drug metabolism [25] . In addition, modulation of alternative splicing can also account for primary or secondary resistance to targeted therapies as previously demonstrated for the Ikaros splice variant Ik6 that drives resistance to imatinib in breakpoint cluster region-Abelson positive ALL cell lines [26] , or for the V600E B-Raf (BRAF) splice variant BRAF3-9, which results from skipping of BRAF exons 4-8, and correlates with acquired resistance to vemurafinib in melanoma patients [27] . As management of cancerous patients with primary/acquired resistance to targeted therapies remains a significant challenge with therapeutic, social, and economic impacts, these data provide the rationale for targeting RNA splicing in cancer. In this setting, it was proposed that spliceosome mutants represent a driver force in some tumors, which may thus be sensitive to spliceosome inhibitors. However, as demonstrated very recently, key driver oncogenes such as Myc can also determine the sensitivity to spliceosome inhibitors of tumor cells lacking spliceosome mutations [28] . Therefore, these results pave the way for testing spliceosome inhibitors in a large variety of cancers whatever their spliceosome mutational status. Besides targeting spliceosome components, mRNASeq approaches recently provided evidence that small molecules inhibiting the serine/arginine-rich proteins kinases CLKs and SRPKs favor the production of splice variants with premature stop codon, thereby leading to protein depletion for multiple genes, including those involved in growth and survival pathways, such as S6K, epidermal growth factor receptor, EIF3D, and poly (ADPribose) polymerase [29] . Small-molecule inhibitors of SRPK1, namely SPHINX and SRPIN340, were also found to switch the splicing of VEGF-A toward the antiangiogenic splice variant VEGF 165 b in prostate cancer cells and to decrease tumor growth in an orthotopic mouse model [30] . However, adding another level of complexity, both oncogenic and tumor suppressive functions of SRPK1 were recently highlighted [31
In addition, in luminal breast cancer cells, CLK2 downregulation was reported to mediate EMT and splicing of target genes involved in cancer cell invasion and metastasis [33] . Therefore, before targeting serine/arginine-rich-phosphorylating kinases for therapeutic purpose, we have to keep in mind that deleterious effects might occur depending on the tumor type and microenvironment.
At the molecular level, recent preclinical studies also demonstrated that sudemycin E, a general spliceosome SF3B inhibitor, binds to SF3B1 and induces its displacement from nucleosome causing a rapid change in alternative premRNA splicing and a G2 arrest that correlates with a loss of the H3K36me3 modification in chromatin encoding spliced exons [34 & ]. The recruitment of splicing factors and adaptator proteins through specific histone marks act in a coordinated manner to regulate alternative splicing [35] . H3K36me3 is a modification significantly enriched in actively transcribed gene bodies and around the intron-exon boundaries of included exons. Very interestingly, a recent study demonstrated that AKT1 and AKT3 phosphorylate IWS1, a RNA processing regulator, and allow the recruitment of the histone-methyltransferase SET2, the trimethylation of H3K36 and the splicing of fibroblast growth factor receptor-2 (FGFR2) [36 && ]. Importantly, the authors further demonstrated that IWS1 phosphorylation correlates with AKT phosphorylation and FGFR2 splicing pattern in LUC patients. This study provides evidence that direct cross-talks between kinases involved in cell proliferation and/or apoptosis, RNA machinery and chromatinremodeling enzymes exist to control alternative splicing in tumor. Whether and how spliceosome inhibitors, used or not in combination with other therapies such as chemotherapies, impact on these signaling networks require therefore deepened investigations. Furthermore, in chronic lymphocytic leukemia cells, the combination of sudemycin with ibrutinib, a Bruton's tyrosine kinase (BTK) inhibitor, resulted in an enhanced cytotoxic effect involving the splicing of IBTK, a physiological inhibitor of BTK [37] . Moreover, spliceostatin A or its analogue meayamycin B was found to limit cell proliferation of vemurafenib-resistant cells by decreasing the amount of the BRAF3-9 splice variant, to prevent tumor formation, and to slow down the growth of vemurafenib-resistant tumors [38 && ]. As a whole, these studies strongly support the future development of novel strategies targeting the spliceosome machinery to overcome drug resistance (Fig. 1) . Hence, the first-in-human phase I clinical trial devoid to identify dose-limiting toxicities using the mRNA splicing inhibitor E107 was published 2 years ago in advanced solid tumor patients, including mainly colorectal or esophageal carcinoma [39] .
CONCLUSION
These last years, the development of high-throughput techniques allowed the identification of a huge number of cancer-related splicing events, together with the discovery of somatic mutations in RNA splicing regulators. These recent insights pave the way for the use of alternative therapeutic strategies designed to target the RNA splicing machinery or to correct specific missplicing events in cancer. However, further deepening of the functional consequences of these aberrant splice patterns is needed to identify those events that are critical for tumor progression and/or emergence of resistance to treatments. These events appear largely dependent on the tumor type, adding another layer of complexity.
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